Despite the scarce reports of anti-PD therapy efficacy in ICC, a previous study reported that PD-1 inhibitor pembrolizumab induced robust and durable efficacy in an advanced cholangiocarcinoma case (8). This evidence concerns the gene PDCD1 and intrahepatic cholangiocarcinoma.